GTS Securities’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,625
Closed -$16.9K 1592
2024
Q3
$16.9K Sell
1,625
-1,565
-49% -$26K ﹤0.01% 3964
2024
Q2
$62.8K Sell
3,190
-950
-23% -$19K ﹤0.01% 3685
2024
Q1
$106K Sell
4,140
-1,975
-32% -$50.6K ﹤0.01% 3514
2023
Q4
$169K Buy
+6,115
New +$373K ﹤0.01% 3622

Other funds holding BLUE

GTS Securities's BLUE Position: Q4 2024 in Review

GTS Securities sold out of bluebird bio (BLUE) in Q4 2024, closing a stake of 706 shares — an estimated $7.34K sold.

GTS Securities first reported a position in BLUE in Q2 2023 and held it in 6 quarters. The position peaked at $159K in Q3 2023. 83 funds tracked by Wall St. Rank hold BLUE as of Q4 2024.

  • GTS Securities reported no remaining bluebird bio position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 706 bluebird bio shares in Q4 2024, an estimated $7.34K.
  • GTS Securities first reported a position in bluebird bio in Q2 2023 and held it in 6 quarters.
  • GTS Securities's bluebird bio position peaked at $159K in Q3 2023.
  • 83 funds tracked by Wall St. Rank held bluebird bio as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.